AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...

Discover Daiichi Sankyo's groundbreaking patent for monoclonal antibodies targeting LAG-3, offering new hope for treating autoimmune diseases with enhanced efficacy.

Daiichi Sankyo and AstraZeneca saw a dip in stock prices after announcing that their Phase III TROPION-Breast01 trial for ...

AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast ...

Shares of Skye Bioscience gained after the San Diego biopharmaceutical company highlighted the safety of its in-development obesity treatment as compared with rivals. AstraZeneca shares slipped after ...

Daiichi Sankyo (OTCPK:DSKYF)(OTCPK:DSNKY) reports that more than 97% of eligible claimants have opted into the product liability settlement program related to olmesartan products... Daiichi Sankyo ...

Despite showing a progression-free survival benefit, the antibody-drug conjugate did not improve overall survival in HR-positive, HER2-negative or -low breast cancer.

This briefing covers notable health news: the US is donating 1 million mpox vaccine doses to Africa, AstraZeneca’s breast ...

The experimental precision drug, developed with Japan's Daiichi Sankyo, did not significantly improve overall survival rates ...

PARIS: European shares closed higher on Monday as a soft business activity reading strengthened the case for more monetary ...

Analysis of the TROPION-Breast01 study showed that treatment with Dato-DXd did not significantly improve overall survival compared with chemotherapy in HR-positive, HER2-low or -negative breast cancer ...

EUROPEAN shares closed higher on Monday as a soft business activity reading strengthened the case for more monetary policy ...